1Cell.Ai is a precision-oncology platform that performs liquid biopsy and NGS-based cancer profiling, isolates viable circulating tumor cells for single-cell multi-omic analysis (DNA/RNA/protein), and delivers machine-learning-driven analytics and automated reporting to support therapy selection, longitudinal monitoring, and biomarker discovery.
Published Sep 19, 2026
Public materials indicate availability via CLIA environments and research-use-only (RUO) contexts in some jurisdictions. Organizations should clarify the intended use and regulatory status of specific assays in each geography (clinical vs RUO).
Public evidence largely consists of vendor press releases and announcements, conference participation, funding and press coverage, and partnership announcements. This makes it more difficult to validate service quality, turnaround-time consistency, and report utility from independent sources.
The 1Cell.Ai homepage and related marketing pages include case-study style metrics and performance claims, but public excerpts did not include full methodology or underlying data in the materials accessed during this review.
Best-fit customers are likely to include:
Good fit when an organization requires:
Get a comprehensive analysis of 1Cell.Ai Inc. including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Organizations that require comprehensive third-party review coverage and standardized SaaS procurement signals
Organizations that require established payer coverage pathways in the US immediately
Organizations seeking low-cost, commodity CGP
Organizations with strict security/compliance gating
Implication: There is limited mainstream B2B software review coverage, which is consistent with 1Cell.Ai operating primarily as a diagnostics laboratory and platform provider rather than a horizontal enterprise SaaS vendor.
Direct, experience-based discussions of 1Cell.Ai are scarce. One Reddit post mentioned OncoIndx genetic tests and reported difficulty obtaining information from the provider and concern about cost; the post had limited engagement at the time of capture, reducing its evidentiary value.
Paraphrased quote from a patient-community post indicating informational and cost concerns: a Reddit user asked whether OncoIndx genetic tests were worth the expense and noted difficulty obtaining information from the provider.
1Cell.Ai announced completion of a CLIA-grade analytical validation study of its OncoIncytes 1080-gene NGS panel and iCare pipeline at a cancer center laboratory. The announcement reported high concordance with certain FDA-cleared orthogonal NGS platforms and performance across FFPE, blood, bone marrow, and multiple tumor types.
Critical evaluation:
The vendor states a body of conference abstracts and posters, including presentations at major oncology meetings. Posters and abstracts can indicate active research but are not equivalent to full peer-reviewed clinical utility publications. Buyers should differentiate between:
1Cell.Ai is a precision-oncology company offering liquid biopsy and NGS-based cancer profiling combined with machine-learning-based analytics. The product portfolio centers on:
These offerings are intended to support therapy selection, monitoring (including minimal residual disease [MRD] and longitudinal monitoring), biomarker discovery, and patient stratification for clinical trials.
1Cell.Ai markets to two overlapping buyer groups:
The company situates itself in the precision oncology segment that focuses on high-complexity, multi-omic approaches, competing indirectly with established ctDNA-based liquid-biopsy providers and tissue comprehensive genomic profiling (CGP) vendors, and more directly with emerging CTC and single-cell multi-omic platforms.